Disclosure. Agenda. I do not have any relevant financial/non financial relationships with any proprietary interests

Similar documents
Cancer Genomics 101. BCCCP 2015 Annual Meeting

The Genetics of Familial Polyposis

Adenomatous Polyposis Syndromes (FAP/AFAP and MAP)

Adenomatous Polyposis Syndromes (FAP/AFAP and MAP)

What All of Us Should Know About Cancer and Genetics

Session 14. Genetic and Genomic Testing and Screening of Children

Primary Care Approach to Genetic Cancer Syndromes

GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Pathology reports, related operative reports and consult letters must be provided with a request for assessment.

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.

Virtual Mentor American Medical Association Journal of Ethics January 2007, Volume 9, Number 1: 6-11.

AllinaHealthSystems 1

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?

Hereditary Colorectal Cancer

Familial and Hereditary Colon Cancer

Cancer statistics (US)

Telephone Disclosure Visual Aid Toolkit: Panel Testing

Familial Adenomatous Polyposis

Familial and Hereditary Colon Cancer

Genetic Risk Assessment for Cancer

Precision Medicine and Genetic Counseling : Is Yes always the correct answer?

BRCA genes and inherited breast and ovarian cancer. Information for patients

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

A Patient s Guide to risk assessment. Hereditary Colorectal Cancer

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.

BowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Developing Guidelines

GHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene

Genetic Risk Assessment for Cancer

Information for You and Your Family

Hereditary Aspects of Pancreatic Cancer

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Integrating Genetics Technology into a Health Care System

Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since. By Dawna Gilchrist, MD, FRCPC, FCCMG

COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University

Genomics and Genetics in Healthcare. By Mary Knutson, RN, MSN

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.

Genetics and Genetic Testing for Autism:

Genetic counseling on VHL. Ignacio Blanco, MD PhD Genetic Counseling and Clinical Genetics Program Germans Trias Hospital Badalona, Spain

WELCOME. Taking Care of Your Health. April 30, 8 am to noon

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

CANCER GENETICS PROVIDER SURVEY

Genetic Determinants, Risk Assessment and Management

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC

Classification of polyposis syndromes two major groups. Adenomatous polyposis syndromes. Hamartomatous polyposis syndromes

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious

NEWBORN SCREENING FOR SICKLE CELL DISEASE Progress Towards Improved Outcomes for Children and Families

Lori Carpenter, MS, LCGC Saint Francis Hospital

12: BOWEL CANCER IN FAMILIES

Result Navigator. Positive Test Result: STK11. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Genetic screening. Martin Delatycki

Metabolic Liver Disease

Case Studies and Informed Consent. Ashley Cannon, PhD, MS, CGC Genomics Immersion Course 10/14/2015

Result Navigator. Positive Test Result: CDH1. After a positive test result, there can be many questions about what to do next. Navigate Your Results

PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

The Patient Perspective: diagnostic Exome Sequencing

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Hereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD

Original Policy Date

Hereditary Cancer Update: What do GPOs need to know?

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Updates in Cancer Genetics & Genomics

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women

GI EMERGENCIES Acute Abdominal Pain

Update on Hereditary Gastric Cancer. Dr. Savtaj Brar MD MSc Surgical Oncologist Assistant Professor of Surgery

GENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE

Non-covered ICD-10-CM Codes for All Lab NCDs

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Genetics

YES. If yes, indicate what types of tumors/polyps and age of onset:

Illumina Clinical Services Laboratory

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014

Should Universal Carrier Screening be Universal?

Disclosure. Polyps in Pediatrics. Learning Objectives. Case Presentation I. Case Presentation II

Genetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry

Clinical Genetics Service

Does Cancer Run in Your Family?

Preventive care guidelines Blue Cross and Blue Shield of Minnesota

Lessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute

HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK

CANCER SCREENING USPSTF AND BEYOND. DeAnn Cummings, MD March 3, 2018

Red flags for clinical practice - guidance on indicators that your patient may have a genetic condition

Colorectal Cancer in 2006: New Developments

HBOC. Jessica M. Salamone, ScM, CGC

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Result Navigator. Positive Test Result: PTEN. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Neurogenetics Genetic Testing and Ethical Issues

Does Cancer Run in Your Family?

BAYLOR SCOTT & WHITE HEALTH GENETICS QUESTIONNAIRE PATIENT INFORMATION

Cancer Conversations

patient guide Hereditary Cancer genetic testing panels Because knowing your risk can mean early detection and prevention

Transcription:

Luis Rohena, MD Chief, Medical Genetics San Antonio Military Medical Center Assistant Professor of Pediatrics USUHS & UTHSCSA 15JUNE2014 51st Annual Teaching Conference Pediatrics for the Practitioner Disclosure No Relevant Financial Relationships with Commercial Interests. Nothing to disclose. Agenda When to perform genetic testing in children Ethical dilemmas encountered testing children Review commonly encountered problems: Case based Review AAP and ACMG policy statements on testing in children

Genetic Testing Benefits Clarify and confirm a diagnosis Medical management Understand recurrence risks Reproductive issues Prenatal diagnosis/adoption/ivf/pgd/ Donor egg or sperm Genetic Testing Risks Anxiety Change in self image/ family dynamics Discrimination employment, insurance The risks may not be immediate or obvious Informed consent Discussion about possibilities for result Positive, negative, variant of unclear significance Implications for management

Genetic screening of minors is relatively common. Every year approximately 4 million infants in the United States undergo newborn screening for metabolic, hematologic, and endocrine disorders for which early treatment may prevent or reduce morbidity or mortality. 3 principles in newborn screening Clear benefit to the child System in place for confirmation of diagnosis Treatment and follow up must be available for affected newborns

Informed consent for newborn screening An effort should be made to educate couples about newborn screening prior to delivery Should screening be optional or mandatory? Those that argue it should be mandatory state that the child s welfare is more important than the parental choice. Besides the Newborn Screening Program, genetic testing of children is less commonly performed. Diagnostic testing may be performed on a child with signs or symptoms of a potential genetic condition or for treatment decisions. Genetic testing may also be performed on an asymptomatic child with a positive family history for a specific genetic condition. Case #1 29 year old male with known diagnosis of familial adenomatous polyposis (FAP) confirmed with DNA studies accompanies his 10 year old daughter to appointment with pediatrician. Requests genetic testing for daughter

FAP Review FAP is a colon cancer predisposition syndrome 100s to 1000s of polyps develop. Av age of polyps development is 16 (range 7 36 years). Colon cancer is inevitable without colectomy. The mean age of colon cancer diagnosis in untreated individuals is 39 years (range 34 43 years). Extracolonic manifestations in some cases can include: stomach polyps, osteomas, dental anomalies, CHRPE, desmoid tumors FAP Review APC gene Autosomal Dominant Genetic testing detects approximately 90% of mutations Management/Screening Annual colonoscopy at 10 yrs of age Annual upper endoscopy Ophthalmology evaluation Dental exam with panoramic x ray If under age 5, hepatoblastoma screening (liver US and AFP) Annual physical exam Prophylactic colectomy in most cases (when 20 30 adenomas are found) Do we say YES to the TEST? YES Result has implications for management during childhood If dad has a known FAP causing mutation, we can test child for the specific mutation present in dad If present, confirms diagnosis in child and proceed with management If negative, excludes diagnosis in child If dad has not had genetic testing, testing should be done for the father first If father has been tested and no mutation identified, testing for child would not be informative Child should be screened as if affected

Case #2 A 10 year old boy presents with unsteady gait and tremors. Features suggestive of Friedreich s ataxia. FDRA review Associated with a slowly progressive ataxia Mean onset of symptoms occurs between 10 15 years of age. Associated with dysarthria, muscle weakness, lower limb spasticity and absent reflexes, scoliosis, bladder dysfunction, cardiomyopathy, diabetes mellitus Autosomal recessive Usually wheelchair bound by 18 years Treatment is generally symptomatic Do we say YES to the TEST? YES Already showing features Will clarify diagnosis

Case #2 Continued Genetic testing was able to confirm a diagnosis in the patient. Parents request pre symptomatic testing for the patient s younger siblings, ages 6 and 8. Do we say YES to the TEST? Can the parents speak for the rights of the children It is generally an untreatable condition, what are the benefits of this testing? Can you order a test just because the parents request it? Are you worried that the parents will treat those that test positive differently from those that test negative? Carrier testing What if the parents were interested in learning the carrier status of the children, rather than predictive testing? Ex. Tay sachs

Carrier Testing Concerns about confusion regarding the difference between being an asymptomatic carrier and being affected could lead to stigma and discrimination Historical example includes programs for sickle cell screening in the 1970s which led to misinformation and discrimination. Arguments for carrier testing in children and adolescents include increase in reproductive choices Carriers are sometimes identified through newborn screening but this is not the purpose of the screening Case #3 A 45 year old mother was recently diagnosed with breast cancer. Genetic testing found that the mother carries a BRCA 1 mutation. She brings her 8 year old daughter to the pediatrician requesting BRCA testing. Hereditary Breast and Ovarian Cancer (HBOC) review Autosomal dominant Risk to child is 50% Risk of breast cancer is up to 85% Risk of ovarian cancer is up to 40% Management/Screening Annual mammogram and breast MRI beginning at 25 yrs Transvaginal ultrasound, CA 125 annually Consideration of prophylactic surgeries including mastectomy and BSO

Do we say YES to the TEST? NO Result does not have implications for management during childhood No change in management at this time Risks include lack of autonomy for minor Possibility of insurance discrimination Psychosocial implication What if the child is 18? or 16? What if mom is pregnant and desires prenatal testing? A father comes to clinic with his children based on their mother s diagnosis of Huntington disease. He is inquiring about whether he should have his children tested.

Huntington disease review (HD) is a progressive disorder of motor, cognitive, and psychiatric disturbances. The mean age of onset is 35 to 44 years and the median survival time is 15 to 18 years after onset. The only treatment is symptomatic management HD review Autosomal dominant Risk to child is 50% Lifetime risk of developing symptoms is 100% Treatment is symptom based and limited. There is no known medical benefit of early diagnosis. Multidisciplinary approach is recommended for those considering genetic testing Neurology Psychology Genetics Do we say YES to the TEST? No Testing is NOT done for minors at risk for HD Only 10 20% of adults at risk for HD opt for presymptomatic genetic testing.

Case 4 continued What would you say about prenatal diagnosis for HD? Additional concerns Genetic testing is now being offered to identify individuals at increased risk for common adult onset conditions such as hypertension, diabetes, and Alzheimer disease. Without clearly helpful treatments or methods of prevention, genetic testing may have more risk than benefit. Research suggests that many parents may be interested in having their children tested for common adult onset diseases. Pediatrics (2011) Parents' Attitudes Toward Pediatric Genetic Testing for Common Disease Risk Wilfond et al.

AAP and ACMG Policy Statements Decisions about whether to offer genetic testing and screening should be driven by the best interest of the child. Genetic testing is best offered in the context of genetic counseling. Diagnostic Testing Should be performed in a child with symptoms of a genetic condition, the rationale for genetic testing is similar to that of other medical diagnostic evaluations. When performed for therapeutic purposes, pharmacogenetic testing of children is acceptable. Newborn Screening The AAP and ACMG support the mandatory offering of newborn screening for all children. After education and counseling about the substantial benefits of newborn screening, its remote risks, and the next steps in the event of a positive screening result, parents have the option of refusing the procedure, and an informed refusal should be respected.

Carrier Testing The AAP and ACMG do not support routine carrier testing in minors when such testing does not provide health benefits in childhood. For pregnant adolescents or for adolescents considering reproduction, genetic testing and screening should be offered as clinically indicated, and the risks and benefits should be explained clearly. Predictive Genetic Testing Parents or guardians may authorize predictive testing for asymptomatic children at risk of childhood onset conditions. Predictive genetic testing for adult onset conditions generally should be deferred unless an intervention initiated in childhood may reduce morbidity or mortality. Predictive Genetic Testing For ethical and legal reasons, health care providers should not provide predictive genetic testing to minors without the involvement of their parents or guardians.

Disclosure At the time of genetic testing, parents or guardians should be encouraged to inform their child of the test results at an appropriate age. Parents or guardians should be advised that, under most circumstances, a request by a mature adolescent for test results should be honored. Disclosure Results from genetic testing of a child may have implications for the parents and other family members. Health care providers should encourage patients and families to share this information and offer to help explain the results to the extended family or refer them for genetic counseling. Misattributed paternity, use of donor gametes, adoption, or other questions about family relationships may be uncovered incidentally whenever genetic testing is performed, particularly when testing multiple family members.

SUMMARY The best interest of the child should guide decisions about whether a child should undergo genetic testing Generally, genetic testing should be postponed in testing for adult onset conditions and carrier testing for recessive conditions There is some ambiguity regarding childhood disorders for which there is no medical interventions. There may be some cases where testing of an adolescent is appropriate. References: American Academy of Pediatrics & American College of Medical Genetics, Policy statement: Ethical and policy issues in genetic testing and screening of children. Pediatrics, published online 21 February 2013 (10.1542/peds.2012 3680). B. M. Knoppers, K. Sénécal, P. Borry, D. Avard, Wholegenome sequencing in newborn screening programs. Sci.Transl. Med. 6, 229cm2 (2014). R. Sugalski, SAMMC QUESTIONS?